Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Factors predicting outcomes in patients with AL amyloidosis treated with daratumumab

Camille Vanessa Edwards • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab

Camille Vanessa Edwards, MD, Boston University School of Medicine, Boston, MA, comments on the results of a study investigating factors that can predict the outcomes of patients with AL amyloidosis treated with daratumumab. The study found that an NT-proBNP greater than 8500, gain of chromosome 1q, and a treatment period of less than 12 months were all associated with poorer outcomes in this patient population. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Camille Vanessa Edwards

3:59
Using an iPSC-derived model to understand the mechanisms driving light chain-induced cardiotoxicity
Camille Vanessa Edwards • 7 Sep 2022
2:41
Optimizing the use of daratumumab in AL amyloidosis
Camille Vanessa Edwards • 7 Sep 2022
2:38
The role of the multidisciplinary team in cardiac amyloidosis
Camille Vanessa Edwards • 7 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals